{"denoms":[{"counts":[{"groupId":"BG000","value":"152"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"161"},{"groupId":"BG003","value":"337"}],"units":"Participants"}],"groups":[{"description":"Participants received 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.","id":"BG000","title":"Part 1: Cohort A: METex14 Skipping Alterations"},{"description":"Participants received 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.","id":"BG001","title":"Part 1: Cohort B: MET Amplification"},{"description":"Participants received 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.","id":"BG002","title":"Part 2: Cohort C: Confirmatory Part for METex14 Skipping Alterations"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.97","value":"73.0"},{"groupId":"BG001","spread":"9.17","value":"62.3"},{"groupId":"BG002","spread":"9.24","value":"71.5"},{"groupId":"BG003","spread":"9.47","value":"71.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"73"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"86"},{"groupId":"BG003","value":"162"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"79"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"75"},{"groupId":"BG003","value":"175"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"3"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"148"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"157"},{"groupId":"BG003","value":"328"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"6"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"07"},{"groupId":"BG002","value":"68"},{"groupId":"BG003","value":"113"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"01"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"02"},{"groupId":"BG003","value":"3"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"108"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"87"},{"groupId":"BG003","value":"212"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"05"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"04"},{"groupId":"BG003","value":"9"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"All participants in Cohort A, Cohort B and Cohort C who were administered at least 1 dose of tepotinib."}